Hidradenitis Suppurativa study: Lutikizumab
Official title A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
ClinicalTrials.gov ID: NCT06524635
What this study is testing
What is Lutikizumab?
An investigational subcutaneous injectable medicine being studied as a potential treatment for moderate to severe hidradenitis suppurativa and atopic dermatitis. It is designed to block the activity of interleukin‑1α and interleukin‑1β, proteins that drive inflammation.
Also referred to as ABT‑981.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to see how the drug lutikizumab affects specific molecules in the body for people with these skin conditions.
- Who it's for
- Adults with moderate to severe hidradenitis suppurativa or atopic dermatitis.
- What's involved
- Participants will receive under-the-skin injections of lutikizumab and attend regular visits for medical checks, blood tests, and sample collections.
- Time commitment
- The main study lasts up to 30 weeks, with an optional extension of up to 140 weeks for some participants.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Participants with a diagnosis of moderate-to-severe HS for at least 6 months prior to Baseline as determined by the investigator
- Participants naïve to biologic treatment for HS or must have a prior inadequate response or loss of response to anti-TNF therapy for HS (\>= 12 weeks...
- Participants with a diagnosis of moderate-to-severe AD with onset of symptoms at least 1 year prior to Baseline.
- Participants naïve to biologic treatment for AD or must have a prior inadequate response or loss of response to dupilumab for AD (defined as \>= 8...
You likely can't join if
- History of any malignancy within the last 5 years except for successfully treated nonmelanoma skin cancer (NMSC) or localized carcinoma in situ of...
- History of active skin disease (other than HS for Sub-Study 1 or AD for Sub-Study 2) that could interfere with the assessment of HS (for Sub-Study 1)...
The study team makes the final eligibility decision.
Where it is enrolling
- Sacramento, California, United States
- Ann Arbor, Michigan, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Sacramento, California, United States; Ann Arbor, Michigan, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.